Effect of a comprehensive programme to provide universal access to care for sputum-smear-positive multidrug-resistant tuberculosis in China: a before-and-after study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

China has a quarter of all patients with multidrug-resistant tuberculosis (MDRTB) worldwide, but less than 5% are in quality treatment programmes. In a before-and-after study we aimed to assess the effect of a comprehensive programme to provide universal access to diagnosis, treatment, and follow-up for MDRTB in four Chinese cities (population 18 million).

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Glob Health

Title: The Lancet. Global health

ISSN (Electronic): 2214-109X

ISSN (Print): 2214-109X

Publication date (Electronic): Apr 2015

Volume: 3

Issue: 4

Affiliations

[1 ] National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.

[2 ] Center for Health Management and Policy, Shandong University, Jinan, Shandong, China.

[3 ] Chinese Anti-tuberculosis Association, Beijing, China.

[4 ] Bill & Melinda Gates Foundation, China Office, Beijing, China.

[5 ] National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China. Electronic address: wangyu@chinacdc.cn.

Article

Publisher Item ID: S2214-109X(15)70021-5

DOI: 10.1016/S2214-109X(15)70021-5

PubMed ID: 25794675

SO-VID: 5adcf8b4-4908-4877-ba19-00fc7b5e1798

History

Data availability:

Comments

Comment on this article

scite_

Cited by 29

See all cited by

- Version 1